232 related articles for article (PubMed ID: 23741443)
1. Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma.
Lu L; Sun HC; Zhang W; Chai ZT; Zhu XD; Kong LQ; Wang WQ; Zhang KZ; Zhang YY; Zhang QB; Ao JY; Li JQ; Wang L; Wu WZ; Tang ZY
PLoS One; 2013; 8(5):e65023. PubMed ID: 23741443
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY
Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424
[TBL] [Abstract][Full Text] [Related]
3. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
4. Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
Wang H; Xu L; Zhu X; Wang P; Chi H; Meng Z
Oncol Rep; 2014 Oct; 32(4):1465-72. PubMed ID: 25070581
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
[TBL] [Abstract][Full Text] [Related]
7. Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30.
Guo Z; Cao M; You A; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Sun H; Zhang T
Cancer Sci; 2016 Apr; 107(4):507-13. PubMed ID: 26752068
[TBL] [Abstract][Full Text] [Related]
8. By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Li S; Dai W; Mo W; Li J; Feng J; Wu L; Liu T; Yu Q; Xu S; Wang W; Lu X; Zhang Q; Chen K; Xia Y; Lu J; Zhou Y; Fan X; Xu L; Guo C
Int J Cancer; 2017 Dec; 141(12):2571-2584. PubMed ID: 28857200
[TBL] [Abstract][Full Text] [Related]
9. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.
Zhang QB; Sun HC; Zhang KZ; Jia QA; Bu Y; Wang M; Chai ZT; Zhang QB; Wang WQ; Kong LQ; Zhu XD; Lu L; Wu WZ; Wang L; Tang ZY
PLoS One; 2013; 8(2):e55945. PubMed ID: 23409093
[TBL] [Abstract][Full Text] [Related]
10. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of SDF1-α expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma.
Lu L; Lu M; Pei Y; Chen J; Qin L; Zhu W; Jia H
Acta Biochim Biophys Sin (Shanghai); 2015 Dec; 47(12):988-96. PubMed ID: 26607439
[TBL] [Abstract][Full Text] [Related]
12. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
[TBL] [Abstract][Full Text] [Related]
13. A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo.
Xu YY; Chen L; Wang GL; Zhou JM; Zhang YX; Wei YZ; Zhu YY; Qin J
BMC Cancer; 2013 Nov; 13():527. PubMed ID: 24195809
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C
Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib inhibits migration, invasion, and vasculogenic mimicry of hepatocellular carcinoma via targeting ID1-mediated EMT.
Zhang N; Zhang S; Wu W; Lu W; Jiang M; Zheng N; Huang J; Wang L; Liu H; Zheng M; Wang J
Mol Carcinog; 2021 Feb; 60(2):151-163. PubMed ID: 33428809
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
Ha TY; Hwang S; Moon KM; Won YJ; Song GW; Kim N; Tak E; Ryoo BY; Hong HN
Anticancer Res; 2015 Apr; 35(4):1967-76. PubMed ID: 25862849
[TBL] [Abstract][Full Text] [Related]
17. The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.
Xu J; Lin H; Li G; Sun Y; Chen J; Shi L; Cai X; Chang C
EBioMedicine; 2016 Oct; 12():55-67. PubMed ID: 27688096
[TBL] [Abstract][Full Text] [Related]
18. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
Liu J; Liu Y; Meng L; Ji B; Yang D
Int J Med Sci; 2017; 14(6):523-529. PubMed ID: 28638267
[No Abstract] [Full Text] [Related]
20. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
